Royalty Pharma plc
RPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $2 |
| % Growth | -3.9% | 5.2% | -2.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $2 | $2 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | $2 | $0 |
| Operating Expenses | $1 | $1 | $2 | $1 |
| Operating Income | $1 | $1 | $0 | $1 |
| % Margin | 57.1% | 63.4% | 13.7% | 62.5% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | $1 | $2 | $0 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $1 | $1 | $0 | $1 |
| % Margin | 37.9% | 48.2% | 1.9% | 27.1% |
| EPS | 1.917 | 2.535 | 0.098 | 1.494 |
| % Growth | -24.4% | 2,492.4% | -93.5% | – |
| EPS Diluted | 1.912 | 2.534 | 0.098 | 1.494 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $2 | $2 | $0 | $1 |
| % Margin | 68.8% | 80.2% | 18.9% | 62.5% |